Advances in drug development and neurotechnology over the last century have noticeably increased our ability to target cognitive-behavioral networks and help those with physical disabilities. These and future advances could potentially provide a pathway by which to use drugs and/or devices to consistently enhance human cognition and behavior, rather than just treat or manage the symptoms of medical conditions.
In this episode Richard Lewis, news officer at the University of Iowa, speaks with Dr. Ted Abel, Professor at the University of Iowa and Director of the Iowa Neuroscience Institute. As a trained biochemist and molecular biologist, the work in Dr. Abel’s lab focuses on using mouse models to understand the molecular mechanisms of memory storage and the molecular basis of neurodevelopmental and psychiatric disorders.
Leaders from the National Institutes of Health (NIH) on February 26 presented exciting updates on the Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative in a congressional briefing sponsored by the American Brain Coalition, the American Academy of Neurology, and the Society for Neuroscience in cooperation with the
As Brian Bingham aptly pointed out in his blog post, everyone must take action to reduce stigma – both that of using “criminalized drugs,” and that of having disorders like alcoholism, depression and anxiety. Since the turn of the 20th century, the public, the American government, and several other countries have been cultivating a culture of:
A. Drugs are bad.
B. People who take drugs are bad.
C. There are no exceptions to points A and B.